Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1996 Aug 1;155(3):285–289.

Prevalence of factor V Leiden in a Canadian blood donor population.

D H Lee 1, P A Henderson 1, M A Blajchman 1
PMCID: PMC1487985  PMID: 8705907

Abstract

OBJECTIVE: To determine the prevalence of factor V Leiden in a Canadian blood donor population. DESIGN: Cross-sectional laboratory study. SETTING: Hamilton Centre of the Canadian Red Cross Society. PARTICIPANTS: Volunteer donors who attended Hamilton Centre blood donor clinics over a 4-day period in August 1994; blood samples from 356 people were evaluable. OUTCOME MEASURES: Presence of factor V Leiden. RESULTS: Factor V Leiden was detected in 19 of the 356 people, for a prevalence rate of 5.3% (95% confidence interval 3.0% to 7.6%). All 19 people were shown to be heterozygous for the mutation. CONCLUSION: Factor V Leiden is common in the Canadian population. Its prevalence is similar to that reported in other Western countries. These data are relevant in the clinical management of patients at risk for venous thrombosis and those with recurrent thrombotic disorders.

Full text

PDF
288

Images in this article

286Fig. 1
on p.286
287Fig. 2
on p.287

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beauchamp N. J., Daly M. E., Hampton K. K., Cooper P. C., Preston F. E., Peake I. R. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol. 1994 Sep;88(1):219–222. doi: 10.1111/j.1365-2141.1994.tb05005.x. [DOI] [PubMed] [Google Scholar]
  2. Bertina R. M., Koeleman B. P., Koster T., Rosendaal F. R., Dirven R. J., de Ronde H., van der Velden P. A., Reitsma P. H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994 May 5;369(6475):64–67. doi: 10.1038/369064a0. [DOI] [PubMed] [Google Scholar]
  3. Bertina R. M., Reitsma P. H., Rosendaal F. R., Vandenbroucke J. P. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost. 1995 Jul;74(1):449–453. [PubMed] [Google Scholar]
  4. Cushman M., Bhushan F., Bovill E., Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost. 1994 Oct;72(4):647–647. [PubMed] [Google Scholar]
  5. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995 Jul;74(1):139–148. [PubMed] [Google Scholar]
  6. Griffin J. H., Evatt B., Wideman C., Fernández J. A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993 Oct 1;82(7):1989–1993. [PubMed] [Google Scholar]
  7. Heeb M. J., Kojima Y., Greengard J. S., Griffin J. H. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood. 1995 Jun 15;85(12):3405–3411. [PubMed] [Google Scholar]
  8. Hellgren M., Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995 Jul;173(1):210–213. doi: 10.1016/0002-9378(95)90192-2. [DOI] [PubMed] [Google Scholar]
  9. Koster T., Rosendaal F. R., de Ronde H., Briët E., Vandenbroucke J. P., Bertina R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993 Dec 18;342(8886-8887):1503–1506. doi: 10.1016/s0140-6736(05)80081-9. [DOI] [PubMed] [Google Scholar]
  10. Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995 Apr 6;332(14):912–917. doi: 10.1056/NEJM199504063321403. [DOI] [PubMed] [Google Scholar]
  11. Samani N. J., Lodwick D., Martin D., Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet. 1994 Dec 17;344(8938):1709–1710. doi: 10.1016/s0140-6736(94)90495-2. [DOI] [PubMed] [Google Scholar]
  12. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  14. Takamiya O., Ishida F., Kodaira H., Kitano K. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population. Thromb Haemost. 1995 Sep;74(3):996–996. [PubMed] [Google Scholar]
  15. Tzall W. R., Sciacca R. R., Blood D. K., McCarthy D. M., Cannon P. J. Bayesian analysis using Fourier transforms of thallium-201 scintiscans to predict the presence of coronary artery disease. Am J Cardiol. 1984 Aug 1;54(3):289–293. doi: 10.1016/0002-9149(84)90185-1. [DOI] [PubMed] [Google Scholar]
  16. Vandenbroucke J. P., Koster T., Briët E., Reitsma P. H., Bertina R. M., Rosendaal F. R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994 Nov 26;344(8935):1453–1457. doi: 10.1016/s0140-6736(94)90286-0. [DOI] [PubMed] [Google Scholar]
  17. Voorberg J., Roelse J., Koopman R., Büller H., Berends F., ten Cate J. W., Mertens K., van Mourik J. A. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994 Jun 18;343(8912):1535–1536. doi: 10.1016/s0140-6736(94)92939-4. [DOI] [PubMed] [Google Scholar]
  18. Zöller B., Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994 Jun 18;343(8912):1536–1538. doi: 10.1016/s0140-6736(94)92940-8. [DOI] [PubMed] [Google Scholar]
  19. van Bockxmeer F. M., Baker R. I., Taylor R. R. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med. 1995 Mar;1(3):185–185. doi: 10.1038/nm0395-185. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES